MHRA nod for AbbVie's Aquipta in migraine prevention
AbbVie (NYSE: ABBV) has announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Aquipta (atogepant) for the prophylaxis of migraine in adults who have at least four migraine days per month.
The US drugmaker’s oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist, which is branded in North America as Qulipta, recently received European Union marketing authorization in the same indication.
"We are currently working with the regulatory authorities to bring this potential treatment to eligible patients as soon as possible"The marketing authorization is supported by data from two pivotal Phase III studies evaluating Aquipta 60mg once-daily in adults living with episodic and chronic migraine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze